CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports First Quarter 2024 Financial Results Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025
CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports First Quarter 2024 Financial Results Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025
CNS Pharmaceuticals | 8-K:CNS Pharmicals公佈2024年第一季度財務業績評估伯魯比辛的潛在關鍵GBM研究已完成註冊;Topline數據預計將於2025年上半年發佈